CGTLive’s Weekly Rewind – October 13, 2023


Review top news and interview highlights from the week ending October 13, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. bluebird's HGB-210 Trial Hopes to Support First SCD Gene Therapy Approval

Lovo-cel is currently being evaluated in the phase 3 HGB-210 study and has a PDUFA date of December 20, 2023.

2. Thomas Povsic, MD, PhD, on Ongoing Research With XC001 Angina Gene Therapy

The interventional cardiologist and professor, Duke University School of Medicine, discussed other populations that may benefit from XC001 and the challenges and opportunities with a surgical delivery of treatment.

3. Antitumor Activity and Bone Regeneration: Tackling Multiple Angles of Osteosarcoma

Fiona Freeman, PhD, assistant professor, University College Dublin, discussed her research into microRNA-29b in suppressing tumor growth and promoting bone remodeling in mice models.

4. Nadezhda Omelchenko, MD, on Treating Rare Sarcomas With Autologous Natural Killer Cell Therapy

The research associate at Cancer Center of Southern California in Santa Monica discussed findings from 3 patients treated with a combination therapy that included NK cell therapy SNK01.

5. AviadoBio Begins Trial for Frontotemporal Dementia Gene Therapy AVB-101

The open-label, multicenter, ascending dose trial is expected to treat approximately 9 patients in total across 2 dose cohorts.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
Omid Hamid, MD, on Clinic Experience With TIL vs CAR-T Therapy Administration
Jeffrey Chamberlain, PhD, on Continuing the Marathon of Muscular Dystrophy Research
N. Nora Bennani, MD, on Diving Deeper Into T-Cell Lymphomas
© 2024 MJH Life Sciences

All rights reserved.